ENTITY
Polaris Group

Polaris Group (6550 TT)

21
Analysis
Health CareTaiwan
Polaris Group of TW researches and develops biological drugs for cancer, small molecular drugs, and other diagnostic reagents. The Company focuses on hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, and acute myeloid leukemia fields. Polaris Group conducts businesses in Taiwan and California.
more
Refresh
01 Oct 2023 10:00

TWSE Short Interest Weekly (Sep 29th): Unimicron Tech, Largan Precision, Wistron, Gigabyte Tech

We analyzed TWSE short interest report for the past week and highlight short interest changes in Unimicron Tech, Largan Precision, Wistron,...

Logo
450 Views
Share
17 Sep 2023 10:00

TWSE Short Interest Weekly (Sep 15th): Wiwynn, Alchip Tech, Realtek Semi

We analyzed TWSE short interest report for the past week and highlight short interest changes in Wiwynn, Alchip Tech, Realtek Semi.

Logo
384 Views
Share
10 Sep 2023 10:00

TWSE Short Interest Weekly (Sep 8th): Realtek Semi, Faraday Tech, Auo, Asustek Computer, Mediatek

We analyzed TWSE short interest report for the past week and highlight short interest changes in Realtek Semi, Faraday Tech, Auo, Asustek Computer,...

Logo
397 Views
Share
bullishPolaris Group
21 Jun 2023 19:30

Polaris Group (6550 TT): Preparing for Filing Marketing Approval of First Drug Candidate in US

Polaris is filing BLA to the FDA for lead drug candidate ADI-PEG 20 as a potential treatment of malignant pleural Mesothelioma, a rare form of...

Logo
455 Views
Share
18 Jun 2023 10:15

TWSE Short Interest Weekly (Jun 16th): Inventec, Quanta Computer, Walsin Lihwa, Asia Vital

We analyzed TWSE short interest report for the past week and highlight short interest changes in Inventec, Quanta Computer, Walsin Lihwa, Asia...

Logo
384 Views
Share
x